Form 4: Rapport Therapeutics COO Sells Shares

Rapport Therapeutics COO Cheryl Gault sold a total of 9,900 shares of common stock across multiple transactions on June 30, 2026, pursuant to a Rule 10b5-1 trading plan.

Summary

• Cheryl Gault, Chief Operating Officer of Rapport Therapeutics, Inc., executed a series of stock sales on June 30, 2026.
• These transactions involved the disposal of a total of 9,900 shares of common stock.
• The sales were conducted under a pre-established Rule 10b5-1 trading plan, adopted on December 10, 2025, which is designed to comply with affirmative defense conditions.
• The weighted average sale price for the transactions ranged from $39.61 to $43.65 per share.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the insider selling, despite the use of a Rule 10b5-1 plan, which can sometimes signal a lack of immediate positive catalysts from the insider's perspective.

Negatives

• The Chief Operating Officer sold a significant number of shares (9,900) which could be perceived negatively by the market.
• The sales occurred at prices between $39.61 and $43.65, indicating a disposal of equity during this price range.

Risks

• The Rule 10b5-1 trading plan is a standard mechanism for insiders to sell shares without facing insider trading accusations, but the act of selling itself can sometimes be interpreted as a lack of confidence in future stock performance by some investors.
• The specific prices at which the shares were sold may indicate a point where the COO felt the stock was valued appropriately for divestment.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Industry Context

StockSavvy.ai notes that insider sales, especially those conducted under a Rule 10b5-1 plan, are common for executives looking to diversify their holdings or meet financial obligations. However, the volume and timing can still influence market perception of the company's near-term prospects.

Stakeholder Impact

• Shareholders may view the COO's sale of shares as a potential negative signal, although the use of a Rule 10b5-1 plan mitigates concerns about insider trading.
• The company's stock price could experience minor downward pressure if the market interprets the sales as a lack of confidence by management.

Key Dates

Recommendation

The filing reports routine insider stock sales executed under a pre-arranged plan, which is a standard practice and does not provide new information about the company's fundamental performance or future prospects that would warrant a change in investment strategy. Therefore, a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Rapport Therapeutics, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Cheryl Gault, COO, Beneficial Ownership